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ABSTRACT 
As a universally common endocrinopathy in women of reproductive age, the 
polycystic ovarian syndrome is characterized by composite clinical phenotypes 
reflecting the contributions of reproductive impact of ovarian dysfunction and metabolic 
abnormalities with widely varying symptoms resulting from interference of the genome 
with the environment through integrative biological mechanisms including epigenetics. 
We have performed a genome-wide DNA methylation analysis on polycystic ovarian 
syndrome and identified a substantial number of genomic sites differentially methylated 
in the whole blood of PCOS patients and healthy controls (52 sites, false discovery 
rate < 0.05 and corresponding p value < 5.68e–06 ), highly consistently replicating 
biological pathways extensively implicated in immunity and immunity-related 
inflammatory disorders (false discovery rate < 0.05) that were reportedly regulated 
in the DNA methylome from ovarian tissue under PCOS condition. Most importantly, 
our genome-wide profiling focusing on PCOS patients revealed a large number of DNA 
methylation sites and their enriched functional pathways significantly associated with 
diverse clinical features (levels of prolactin, estradiol, progesterone and menstrual 
cycle) that could serve as novel molecular basis of the clinical heterogeneity observed 
in PCOS women. 
 
INTRODUCTION 
Polycystic ovarian syndrome (PCOS) is a common 
endocrinological disorder that affects about 10% women 
of reproductive age [1–2]. The syndrome has a complex 
mode of inheritance, in which genomic variants interfere 
with important environmental factors, including  diet,  
life style, leading to heterogeneous expression of the 
syndrome characterized by chronic anovulation or 
infrequent ovulation, obesity, hirsutism, hyperandrogenism 
and polycystic ovaries. As a complex disorder the 
pathophysiology  of  PCOS  involves  both  genetic    and 
environmental contributions [3]. For example, a Dutch 
twin study [4] estimated a high genetic component in 
PCOS with a heritability estimate of over 60%. Moreover, 
previous genetic studies identified  multiple  genomic  
loci associated PCOS [5–6]. Meanwhile, animal studies 
provided evidence that prenatal exposure to excessive 
androgen induced similar phenotypes to PCOS  [7–9]  
and ovarian dysfunction suggesting the important role of 
environment in PCOS pathogenesis. The multifactorial 
nature of PCOS calls for biological functional studies at 
molecular level to elucidate the integrative mechanisms in 
the development of PCOS. 
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Epigenetics focuses on molecular mechanisms  in  
the regulation of gene expression not caused by DNA 
sequence variation. It represents a new frontier in functional 
genomics of complex diseases and serves as a potential 
molecular bridge linking the environment to the genetic 
materials. Among the various mechanisms of epigenetic 
regulation, genomic DNA methylation patterns have been 
widely analysed to investigate the molecular basis of 
complex disorders mediated by genetic and environmental 
factors. In the literature, genome-wide association analyses 
have been performed on PCOS patients and controls by 
comparing DNA methylation levels between the two 
groups measured using high-throughput techniques [10–
13]. However, results from the different  genome-  wide 
analyses have been highly inconsistent. For example, while 
Xu et  al.  [10]  reported  no  significant  difference  in the 
DNA methylome of peripheral blood cells of 20 PCOS 
patients and 20 controls, multiple differentially methylated    
genes    were    identified    by    Shen    et  al. 
[11] in peripheral blood from even a smaller sample size. By 
targeting the ovarian tissue, large numbers of differentially 
methylated genes were found  by both Wang  et al. [12]  
and Yu et al. [13] in their small studies. Nonetheless, the 
detected genes from each study were associated with 
different molecular functions even though both studies were 
conducted on the ovarian tissues. The situation calls for well- 
designed studies on relatively large sample sizes to validate 
and update current findings to look for novel genomic sites 
and biological pathways associated with PCOS. 
This paper reports our recent epigenome-wide 
association study (EWAS) on a relatively large sample 
size of 30 PCOS patients and 30 age-matched healthy 
controls. We present results from analysis on single CpG 
sites (5′—C—phosphate—G—3′, cytosine and guanine 
separated by one phosphate) followed by findings on 
enriched biological pathways significantly associated 
with PCOS condition. Furthermore, we report our novel 
analysis in  associating  genomic  DNA  methylation  
with levels of reproductive hormones in PCOS patients 
including estradiol (E2), luteinising hormone (LH), follicle 
stimulating hormone (FSH), progesterone (P), thyroid 
stimulating hormone (TSH), prolactin (PRL), testosterone 
(TST), which could reveal the molecular basis of the 
observed clinical heterogeneity in PCOS patients. 
RESULTS 
 
Table 1 presents the basic statistics for both PCOS 
and control samples on phenotypes of interest including 
anthropometric measurements: weight, height, body mass 
index (BMI), waist and hip circumference, waist-hip- 
ratio (WHR); blood pressure: systolic and diastolic blood 
pressure (SBP, DBP); menstrual cycle (MC); reproductive 
hormones: E2, LH, FSH, P, TSH, PRL and TST; and 
metabolic variables: fasting immunoreactive insulin (IRI), 
immunoreactive insulin at 2 hours after ingestation of   
75 gram dextrose (IRI2), fasting blood glucose    (GLU), 
blood glucose at 2 hours after ingestation of 75 gram 
dextrose (GLU2), homeostatic model assessment of insulin 
resistance (HOMA-IR). Highly significant differences 
were found for MC, LH and TST between the two groups; 
statistical or borderline differences were also found for 
WHR (p = 0.037), IRI2 (p = 0.026) and GLU2 (p = 0.031), 
all with higher levels in PCOS patients than in controls. 
 
Epigenetic association with PCOS 
We first performed EWAS for single CpGs 
(Manhattan plot shown in Supplementary Figure S1A). 
After correction for multiple testing, a total of 699 CpGs 
(13 X-linked) were found with false discovery rate (FDR) < 
0.20 with corresponding p value < 3.05e-04 (Supplementary 
Table  S1), among them 52 CpGs (1 X-linked) with    FDR 
< 0.05 with corresponding p value < 5.68e-06. As shown  
in Supplementary Table S1, the mean methylation levels of 
significant CpGs range from low to high but are dominated 
by sites of high DNA methylation levels. Figure 1 is a 
volcano plot displaying p value (in log scale) plotted against 
corresponding difference in the mean methylation levels 
between PCOS patients and controls. The coloured spots 
represent 699 CpGs with FDR < 0.2, among them the red 
spots stand for the 52 genome-wide significant CpGs with 
FDR < 0.05 in Supplementary Table S1. The figure displays 
the significance level for hyper- and hypo-methylated CpGs 
without a predominant pattern of increased or decreased 
methylation in patient or control group. The figure also 
shows a symmetric pattern although the top significant 
CpGs tend to be hypermethylated (i.e. increased in mean 
methylation level) in the patient group. Both Supplementary 
Table S1 and Figure 1 show that the significant CpGs are 
those with only small differences in their DNA methylation 
levels between the two groups. 
Based on the EWAS results, we conducted a gene- 
set enrichment analysis (GSEA,  see  Methods  section) 
on the 273 genes linked to the 699 significant CpGs in 
Supplementary Table S1. A total of 22 functional pathways 
were significantly enriched with FDR < 0.05 (Table 2). 
Among the 22 pathways, the top significant ones are 
mainly those involved in immune and inflammatory 
processes with the rest pertaining to biological processes 
including metabolism of proteins and carbohydrates. 
There are in total 4 pathways with FDR < 0.01(the very 
top of Table 2), all are involved in immunity (intestinal 
immune network for IgA production; asthma; O-Glycan 
biosynthesis) and inflammation (viral myocarditis). 
Epigenetic association with clinical features in 
PCOS patients 
 
In addition to comparing DNA methylation between 
PCOS patients and controls, we also conducted EWAS on the 
30 PCOS patients for their clinical features including BMI, MC, 
reproductive hormones (E2, LH, FSH, P, TSH, PRL, TST), 
and  metabolic  variables  (IRI,  IRI2,  GLU,  GLU2, HOMA- 
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Table 1: Descriptive statistics of PCOS and control samples 
  PCOS, n = 30   Control, n = 30 
Median 2.5% 97.5% Median 2.5% 97.5% P value 
Age, year 25 23 30 27 24 31  
Weight, kg 61 47.5 116.9 63 47.8 86 0.90 
Height, cm 160 149.8 175.3 160 154.3 168.3 0.19 
BMI, km/m2 23 19.4 38 23.4 18.1 33.6 0.67 
Waist, cm 80 56.1 114.8 81 66.3 101.5 0.75 
Hip, cm 97 84.8 123.3 98 88.8 115 0.68 
WHR, % 83.7 75.7 102.8 81.1 72.7 94.5 0.04 
SBP, mmHg 110 100 130 110 90 132.5 0.95 
DBP, mmHg 70 60 83.8 70 66 90 0.07 
MC, day 75 28 407 30 25 35 7.09e–10 
E2, pg/ml 49.9 13.8 151.5 45.5 27.9 115.9 0.38 
LH, mIU/ml 14.1 3 25 4.4 1.6 12 5.12e–08 
FSH, mIU/ml 6.4 4.8 8.9 6.3 3.4 11.1 0.63 
P, ng/ml 0.4 0.2 1.1 0.4 0.1 0.9 0.99 
TSH, uIU/ml 1.8 0.5 5.4 1.7 0.6 4.7 0.79 
PRL, ng/ml 10.4 4 55 11.3 5.8 27.2 0.97 
TST, ng/dl 50.6 6.2 94.7 31.4 7.6 62.8 3.30e–04 
IRI, uIU/ml 15.3 2.1 51.6 10.5 5.6 27.3 0.11 
IRI2, uIU/ml 66.4 10.4 300 46.5 13.7 196.5 0.03 
GLU, mmol/l 5.2 4.8 5.7 5.3 4.8 5.9 0.31 
GLU2, 
mmol/l 6.7 4.5 8.8 6.0 3.5 8.4 0.03 
HOMA-IR 3.5 0.5 12.4 2.3 1.3 6.2 0.15 
Abbreviations: WHR: waist to hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; MC: menstrual cycle; E2: 
estradiol; LH: luteinising hormone; FSH: follicle stimulating hormone; P: progesterone; TSH: thyroid stimulating hormone; PRL: 
Prolactin; TST: Testosterone; IRI: immunoreactive insulin; IRI2: IRI at 2 hours after ingestion of 75 g dextrose; GLU: glucose; 
GLU2: GLU at 2 hours after ingestion of 75 g dextrose; HOMA-IR: homeostatic model assessment of insulin resistance. 
 
IR). Multiple CpGs reaching genome-wide significance 
(FDR < 0.05) were found for E2 (87 CpG sites, corresponding 
p value <  8.36e-06, Supplementary  Table  S2);  for  PRL 
(199 CpG sites, corresponding p value < 2.02e-05, 
Supplementary Table S3); and  borderline  significant  for  P 
(3 CpG sites, FDR = 0.06, corresponding p value < 4.30e- 
07, Supplementary Table S4). Only one CpG was found to 
show genome-wide significance for menstrual cycle (1 CpG 
site,  cg08916385  on  chromosome  4  near  gene  GNRHR, 
p = 5.09e-10, FDR = 2.47e-04). Manhattan plots for E2, PRL 
and P are shown in Supplementary Figure S1B, S1C and S1D 
respectively. In Supplementary Figure S1C, CpGs in the HLA 
(human leukocyte antigen) region of chromosome 6 are highly 
associated with PRL in PCOS patients. This is more clearly 
illustrated by the Manhattan plot  for  chromosome  6  with 
the HLA region highlighted with red colour (Figure 2). No 
genome-wide significant association was found for the other 
clinical features. 
Genes linked to CpGs in Supplementary Tables S2– 
S4 were submitted to GSEA to look for gene-sets 
enriched. Significant pathways were found for E2 (2 
pathways) and PRL (10 pathways) (Table 3) with no 
significantly enriched  pathways  for  progesterone.  The 
2 significant functional pathways for E2 include steroid 
hormone biosynthesis and metabolism  of  xenobiotics  
by cytochrome P450 while  the  10  pathways  enriched 
for PRL are dominated by immunity and inflammation 
processes which largely overlap with the pathways in 
Table 2. 
 
DISCUSSION 
Although there have been sizable genome-wide 
studies reporting significant associations between genetic 
variations and PCOS, [5, 6, 14–17] the regulatory patterns 
in  the  molecular  pathogenesis  of  PCOS  has  been,   to 
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date, rarely investigated with only a handful epigenomic 
studies performed on small sample sizes [10–13]. We have 
conducted a larger EWAS on DNA methylation in whole 
blood of 30 PCOS patients and 30 controls. In contrast to 
previous studies, we engaged a stringent adjustment for 
multiple testing in our EWAS and were able to identify 
multiple CpGs reaching genome level significance for 
their association with PCOS or with clinical features in 
PCOS patients. Meanwhile, results from our single site 
analysis also implicate biological pathways that either 
reconfirming previous studies or representing novel 
findings. 
Although our genome-wide epigenetic profiling 
was targeted at whole blood DNA, results are however 
surprisingly highly consistent with a previous study  
using ovarian tissue [12]. Among the top ten significantly 
enriched pathways in this study (Table 2), six overlap with 
the pathways found by Wang et al. [12]. Likewise, in their 
list of top ten most significant pathways, five can be found 
in our 22 functional pathways listed in Table 2. It is even 
more interesting to see that, there are four pathways, i.e. 
viral myocarditis, allograft rejection, graft versus host 
disease and type I diabetes mellitus, appearing consistently 
in the top ten pathways from both studies although each 
targeting at a very different tissue type (whole blood 
versus ovarian tissue). While these results are strongly 
confirmatory and supportive, the high conformity also 
provides further evidence that the easy-to-access whole 
blood could serve as a useful surrogate to hard-to-access 
tissues like ovary to enable non-invasive large scale 
epigenetic studies on human diseases [18]. 
Many of the significant pathways in Table 2 are 
enriched by genes pertaining to immunity (e.g. adaptive 
immune system, class I MHC mediated antigen processing 
and presentation), or biological pathways directly related 
to certain diseases including inflammatory diseases (viral 
myocarditis, asthma, Leishmania infection), autoimmune 
diseases (type 1 diabetes mellitus, systemic lupus 
erythematosus, autoimmune thyroid disease) and immune 
reaction (allograft rejection, graft versus host disease). The 
predominant involvement of immunity-related biological 
pathways emphasizes the crucial role of inflammation 
and immune reaction in the pathogenesis of PCOS. By 
comparing the nationwide Danish population of PCOS 
with a large control group, Glintborg et al. [19] recently 
reported a significantly increased prevalence for diseases 
 
 
 
Figure 1: A volcano plot for the negative log10-transformed p values plotted against the difference in the mean levels 
of DNA methylation at each CpG site between PCOS and controls groups. CpGs reaching genome-wide significance with 
FDR < 0.05 are coloured red and those with 0.05 < FDR < 0.2 coloured purple. 
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Table 2: The 22 functional pathways enriched (FDR < 0.05) by genes linked to CpG sites in 
Supplementary Table S1 
Gene Set Name [# Genes (K)] Description # Genes in Overlap (k) p-value FDR (q-value) 
KEGG: VIRAL 
MYOCARDITIS [73] Viral myocarditis 6 5.07 e
−6 6.59 e−3 
KEGG: INTESTINAL 
IMMUNE NETWORK FOR 
IGA PRODUCTION [48] 
Intestinal immune network 
for IgA production 
 
5 
 
9.91 e−6 
 
6.59 e−3 
KEGG: ASTHMA [30] Asthma 4 2.96 e−5 9.83 e−3 
KEGG: O–GLYCAN 
BIOSYNTHESIS [30] O–Glycan biosynthesis 4 2.96 e
−5 9.83 e−3 
KEGG: LEISHMANIA 
INFECTION [72] Leishmania infection 5 7.21 e
−5 1.46 e−2 
REACTOME: METABOLISM 
OF PROTEINS [518] 
Genes involved in 
Metabolism of proteins 12 7.33 e
−5 1.46 e−2 
KEGG: ALLOGRAFT 
REJECTION [38] Allograft rejection 4 7.67 e
−5 1.46 e−2 
REACTOME: ADAPTIVE 
IMMUNE SYSTEM [539] 
Genes involved in Adaptive 
Immune System 12 1.06 e
−4 1.69 e−2 
KEGG: GRAFT VERSUS 
HOST DISEASE [42] Graft–versus–host disease 4 1.14 e
−4 1.69 e−2 
KEGG: TYPE I DIABETES 
MELLITUS [44] Type I diabetes mellitus 4 1.37 e
−4 1.82 e−2 
REACTOME: POST 
CHAPERONIN TUBULIN 
FOLDING PATHWAY [19] 
Genes involved in Post– 
chaperonin tubulin folding 
pathway 
 
3 
 
1.87 e−4 
 
2.22 e−2 
KEGG: SYSTEMIC LUPUS 
ERYTHEMATOSUS [140] 
Systemic lupus 
erythematosus 6 2.01 e
−4 2.22 e−2 
REACTOME: HEPARAN 
SULFATE HEPARIN HS GAG 
METABOLISM [52] 
Genes involved in Heparan 
sulfate/heparin (HS–GAG) 
metabolism 
 
4 
 
2.64 e−4 
 
2.54 e−2 
KEGG: AUTOIMMUNE 
THYROID DISEASE [53] Autoimmune thyroid disease 4 2.84 e
−4 2.54 e−2 
REACTOME: ANTIGEN 
PROCESSING 
UBIQUITINATION 
PROTEASOME 
DEGRADATION [212] 
 
Genes involved in Antigen 
processing: Ubiquitination & 
Proteasome degradation 
 
 
7 
 
 
2.97 e−4 
 
 
2.54 e−2 
KEGG: INOSITOL 
PHOSPHATE METABOLISM 
[54] 
Inositol phosphate 
metabolism 
 
4 
 
3.05 e−4 
 
2.54 e−2 
REACTOME: O–LINKED 
GLYCOSYLATION OF 
MUCINS [59] 
Genes involved in O–linked 
glycosylation of mucins 
 
4 
 
4.29 e−4 
 
3.36 e−2 
PID AR PATHWAY [61] Coregulation of Androgen receptor activity 4 4.87 e
−4 3.6 e−2 
REACTOME: IMMUNE 
SYSTEM [933] 
Genes involved in Immune 
System 15 5.26 e
−4 3.68 e−2 
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REACTOME: METABOLISM 
OF CARBOHYDRATES [247] 
Genes involved in 
Metabolism of carbohydrates 7 7.37 e
−4 4.9 e−2 
REACTOME: CLASS 
I MHC MEDIATED 
ANTIGEN PROCESSING 
PRESENTATION [251] 
Genes involved in Class 
I MHC mediated antigen 
processing & presentation 
 
7 
 
8.1 e−4 
 
4.98 e−2 
REACTOME: HS GAG 
BIOSYNTHESIS [31] 
Genes involved in HS–GAG 
biosynthesis 3 8.24 e
−4 4.98 e−2 
 
 
Table 3: The functional pathways enriched (FDR < 0.05) by genes linked to CpG sites in 
Supplementary Tables S2–S4 
Gene Set Name [# Genes (K)] Description # Genes in Overlap (k) p-value FDR (q-value) 
Estradiol     
KEGG:STEROID HORMONE 
BIOSYNTHESIS [55] Steroid hormone biosynthesis 3 3.64 e
−5 4.84 e−2 
KEGG:METABOLISM 
OF XENOBIOTICS BY 
CYTOCHROME P450 [70] 
Metabolism of xenobiotics by 
cytochrome P450 
 
3 
 
7.51 e−5 
 
4.99 e−2 
Prolactin     
KEGG: ALLOGRAFT 
REJECTION [38] Allograft rejection 3 3.52 e
−5 2.43 e−2 
KEGG: GRAFT VERSUS 
HOST DISEASE [42] Graft-versus-host disease 3 4.76 e
−5 2.43 e−2 
KEGG: TYPE I DIABETES 
MELLITUS [44] Type I diabetes mellitus 3 5.48 e
−5 2.43 e−2 
KEGG: AUTOIMMUNE 
THYROID DISEASE [53] Autoimmune thyroid disease 3 9.59 e
−5 2.57 e−2 
REACTOME: ENDOSOMAL 
VACUOLAR PATHWAY [9] 
Genes involved in Endosomal/ 
Vacuolar pathway 2 9.64 e
−5 2.57 e−2 
REACTOME: 
NEF MEDIATED 
DOWNREGULATION 
OF MHC CLASS I 
COMPLEX CELL SURFACE 
EXPRESSION [10] 
 
Genes involved in Nef mediated 
downregulation of MHC class I 
complex cell surface expression 
 
 
2 
 
 
1.2 e−4 
 
 
2.67 e−2 
REACTOME: INTERFERON 
SIGNALING [159] 
Genes involved in Interferon 
Signaling 4 1.46 e
−4 2.67 e−2 
REACTOME: INTERFERON 
GAMMA SIGNALING [63] 
Genes involved in Interferon 
gamma signaling 3 1.61 e
−4 2.67 e−2 
KEGG: VIRAL 
MYOCARDITIS [73] Viral myocarditis 3 2.49 e
−4 3.32 e−2 
KEGG: ENDOCYTOSIS [183] Endocytosis 4 2.5 e−4 3.32 e−2 
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such as diabetes, thyroid disease and asthma. In the 
literature, high prevalence of autoimmune thyroiditis was 
also observed in PCOS patients [20–24]. We think that 
our EWAS results based on DNA methylation profiling 
provide strong molecular evidence for the epidemiological 
findings based on clinical data. Overall, both epigenetic 
and epidemiological data suggest a possible autoimmune 
basis in the pathogenesis of PCOS. 
With interest in the genome-wide distribution of 
PCOS related CpGs, we calculated the proportion of CpGs 
in Supplementary Table S1 for their genomic locations 
(open sea, shelf, shore, island) among hyper- and hypo- 
methylated CpGs (Supplementary Figures S2A, S2B) and 
compared them with corresponding proportions in all 
CpGs on the Illumina 450 K array (Supplementary Figure 
S2C). Compared with the whole array, the distribution of 
genomic location for the CpGs in Supplementary Table 
S1 was significantly different characterized by high 
proportions of hypermethylated CpGs on both north and 
south shelves, a low proportion of hypermethylation on 
the island, and a high proportion of hypomethylated CpGs 
in the open sea representing isolated CpGs in the genome. 
The implication of differential genomic distribution of 
hyper- and hypo-methylated CpGs in the transcriptional 
regulation of PCOS requires further investigation. 
Women with PCOS demonstrate markedly clinical 
heterogeneity with the commonly associated features 
neither uniform nor universal [25–26]. Recently, the 
molecular  basis  underlying  the  heterogeneous   clinical 
manifestations of PCOS has been investigated using high- 
throughput omics approaches and reported molecular 
biomarkers for metabolic heterogeneity [27]. We point out 
that their reported findings were based on statistical testing 
without correction for multiple testing thus missing an 
important procedure in analysing very high dimensional 
omics data. Based on genomic DNA  methylation  
profiles measured in our PCOS patients, we were able    
to conduct association analysis of DNA  methylation  
with multiple clinical features including metabolic 
parameters and reported significant findings after strict 
adjustment for multiple testing. Although no genome- 
wide significant results were found for correlating DNA 
methylation with any of the metabolic features (BMI,  
IRI, IRI2, GLU, GLU2, HOMA-IR), highly significant 
epigenetic associations were observed in our PCOS 
subjects on multiple reproductive hormones including E2 
(Supplementary Table S2), PRL (Supplementary Table S3), 
and progesterone (Supplementary Table S4). From Table 1, 
we see that the three hormones have comparable mean 
levels in PCOS patients and healthy controls. However, 
for the two hormones with large number of significant 
CpGs, i.e. E2 (87 CpGs, Supplementary Table S2) and 
PRL (199 CpGs, Supplementary Table S3), their hormone 
levels in the blood displayed larger dispersions in PCOS 
samples as compared with the controls. In Table 3, the 
methylation regulated pathways for E2 include steroid 
hormone biosynthesis and metabolism of xenobiotics by 
cytochrome P450. The two significant biological pathways 
 
 
 
Figure 2: A Manhattan plot for the negative log10-transformed p values for PRL in PCOS patients plotted against 
chromosome location (Mb) for each CpG alone chromosome 6. The HLA region highlighted with red colour harbours CpGs 
highly associated with PRL. 
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for E2 reveal, for the first time, the differential regulation 
in the synthesis of reproductive hormone and in drug 
metabolism [28] by DNA methylation mechanism in 
PCOS patients. 
Perhaps the most important and novel finding in 
this study is the genome-wide significant patterns of DNA 
methylation in association with prolactin level in our 
PCOS group (Supplementary Table S3). Nearly all of the 
10 functional pathways significantly enriched by GSEA 
(Table 3) are involved in immune function and immune- 
mediated inflammatory conditions. The strong involvement 
of immune system in the epigenetic regulation of PRL 
under PCOS  condition  is  further  illustrated  by  Figure 
2 where a remarkably distinct pattern of association is 
shown in the region of major histocompatibility complex 
(MHC) on band 6p21.3 of the short arm of chromosome 6, 
a region harbouring the human leukocyte antigen (HLA) 
genes (marked in red in Figure 2). Diaz et al. [29] recently 
summarized the multiple actions of PRL unrelated to 
reproduction including its role in the immune system in 
promoting proliferation and in inhibiting apoptosis that 
could help to maintain the appropriate number of immune 
cells in physiological conditions and to maintain immune 
tolerance. Meanwhile, clinical studies failed to associate 
higher levels of PRL with PCOS [30] and suggested that 
PCOS  and  hyperprolactinemia  are  two  distinct entities 
[31] although low prolactin can be a metabolic risk 
marker in PCOS patients [32]. Based on these results, one 
could assume that our observed significant association 
between DNA methylation and PRL levels could be a 
phenomenon independent of PCOS and thus should be 
also observable in non-PCOS subjects. To validate the 
assumption, we conducted a EWAS on DNA methylation 
and PRL levels in the 30 control samples of this study.  
No CpG site was significantly associated with PRL levels 
in the healthy controls suggesting that the significant 
association between methylation and PRL is a conditional 
result only observable in PCOS patients. Although our 
conclusion requires further validation, it already provides 
novel suggestive evidence in linking differential DNA 
methylation and immune responses with PRL regulation 
in PCOS samples. 
It has been suggested that epigenetics may be 
involved in the regulation of endometrial gene expression 
during the menstrual cycle in healthy individuals [33]. 
Our study provides new data on DNA methylation and 
menstrual cycle in PCOS patients. Although only one CpG 
(cg08916385) was found, its significance level remained 
extremely high even at genome level after adjustment for 
multiple testing. Most importantly, the CpG is located 
within 1500 bps of the transcription start site (TSS) in  
the promotor region of gonadotropin-releasing hormone 
receptor (GNRHR) gene on chromosome 4. This gene 
encodes the receptor for type 1 gonadotropin-releasing 
hormone. The gene is expressed on the surface of pituitary 
gonadotrope cells as well as lymphocytes, breast,   ovary, 
and prostate. After binding of gonadotropin-releasing 
hormone, the receptor associates with G-proteins that 
activate a phosphatidylinositol-calcium second messenger 
system. Activation of the receptor ultimately causes the 
release of gonadotropic luteinizing hormone (LH) and 
follicle stimulating hormone (FSH). Our result, for the 
first time, points to the important role of DNA methylation 
mediated epigenetic regulation in controlling menstrual 
cycle in PCOS patients which could impact individualized 
treatment and management of the disease. 
In conclusion, we have identified a substantial 
number of CpGs differentially methylated in the whole 
blood samples of PCOS patients and healthy controls, 
highly consistently replicating biological pathways 
extensively implicated in immunity and immunity- 
related inflammatory conditions that were differentially 
regulated in the DNA methylome of ovarian tissue from 
PCOS women. Most importantly, our genome-wide DNA 
methylation profiling focusing on PCOS patients revealed 
a large number of CpG sites and their enriched functional 
pathways significantly associated with diverse clinical 
features (levels of prolactin, estradiol, progesterone and 
menstrual cycle) that could serve as novel molecular basis 
of clinical heterogeneity observed in PCOS women. 
 
MATERIALS AND METHODS 
 
The study samples 
Sample collection was conducted  at  the  Centre  
of Reproductive Medicine, Linyi People’s Hospital, 
Shandong, China. First, 30 patients aged from 22 to 33 
years were recruited from patients diagnosed as PCOS 
according to the 2003 revised diagnostic criteria of 
Rotterdam consensus [34]. Based on the age and BMI of 
the 30 PCOS patients, 30 controls aged from 23 to 32 years 
were then recruited from healthy females of reproductive 
age who volunteered to participate. All participants were 
free from medication and hormone therapy. A written 
informed consent was obtained from each participant. All 
experiments were conducted according to the principles 
of the Declaration of Helsinki. The research was approved 
by the Reproductive Ethics Committee of Linyi People’s 
Hospital. 
 
Clinical biochemistry and reproductive hormone 
From each participant, blood was taken from 
antecubital venous for blood biochemical test following 
routine protocol and meanwhile the blood for DNA 
methylation analysis was immediately stored under −80°C 
at the central laboratory of Linyi People’s Hospital. Fasting 
immunoreactive insulin (IRI) and immunoreactive insulin 
at 2 hours after ingestion of 75 gram dextrose (IRI2) were 
assayed by radioimmunoassay (Beckman Coulter, Inc., 
Suzhou, China). Measurements on reproductive hormones 
www.impactjournals.com/oncotarget 9 Oncotarget  
   
i.e. luteinising hormone (LH), follicle stimulating hormone 
(FSH), estradiol (E2), total testosterone (TST), prolactin, 
progesterone, and thyroid stimulating hormone (TSH) were 
determined by direct chemiluminescence immunoassay 
(Siemens Healthcare Diagnostics Inc; East Walpole, 
Massachusetts, U.S.A) according to the manufacturer’s 
instructions. Serum fasting blood-glucose (GLU) and 
GLU at 2 hours after ingestion of 75 gram dextrose 
(GLU2) were determined by the oxygen electrode method 
(Beckman Coulter, Inc., Suzhou, China). Homeostatic 
model assessment IR (HOMA-IR) was calculated by the 
equation HOMA-IR = GLU*IRI/22.5. 
 
Genome-wide DNA methylation profiling 
Genome-wide DNA methylation level was measured 
using the Illumina’s Infinium HumanMethylation450 
Beadchip assay (Illumina, San Diego, CA, USA) at 
CapitalBio Corporation (http://www.capitalbio.com), a 
certified Illumina service provider in Beijing, China. The 
array interrogates over 480,000 CpG sites across and 
beyond gene and CpG island regions in the human genome. 
All laboratory work for the assay was performed according 
to the manufacturer’s  instructions.  Data  normalization 
was done using the free R package minfi which  employs 
the quantile normalization [35]. At each CpG site, DNA 
methylation level was summarized by calculating a 
methylation “beta” value defined by the Illumina’s formula 
as β = M/(M + U + 100) where M and U are signal intensities 
measured by the methylated and unmethylated probes at a 
CpG site. Probe quality was controlled by the detection p 
value calculated using minfi. A β value with its assigned 
detection p value > 0.01 was treated as missing. CpG sites 
with more than 5% missing data across the samples were 
dropped from the subsequent analysis. Based on the DNA 
methylation data measured in whole blood of each sample 
and published cell-type-specific DNA methylation  data, 
the package minfi estimated blood cell composition in each 
individual for 6 blood cell types: CD8T, CD4T, natural killer 
cell, B cell, monocyte, and granulocyte. The estimated cell 
type proportion was used by minfi to adjust the effects of 
cell composition on DNA methylation levels in each sample 
before downstream statistical analysis. 
For each individual, DNA methylation levels were 
measured on a total of 485512 CpG sites across the 
genome. We  first filtered out 728 CpGs with detection    
p value > 0.01 in more than 5% of the overall samples 
(i.e.   3   samples).   Different   from   other genome-wide 
Data analysis 
 
Clinical data 
 
Comparison of clinical features between PCOS 
patients and controls was done by the non-parametric 
Wilcoxon rank sum test (equivalent to the Mann-Whitney 
test) with consideration that some of the measurements 
(e.g. menstrual cycle) may not follow the normal 
distribution. Likewise, dispersion of clinical data was 
described by calculating the 2.5% and 97.5% quantiles. 
Epigenetic data 
 
For each CpG site, statistical association of DNA 
methylation with clinical features was tested using the 
dmpFinder function provided by the free R package minfi 
with type of analysis specified as “categorical” for PCOS 
status (1 for cases and 0 for controls) and as “continuous” 
for anthropometric and clinical measurements. Continuous 
measurements were tested with linear regression, while 
an F-test was used for categorical features (here PCOS 
status, equivalent to a t-test), both performed on the logit 
transformation of the methylation β values. Multiple 
testing was adjusted by calculating the false discovery 
rate (FDR) using the Benjamini–Hochberg method [36]. 
Genome-wide significance in differential methylation was 
defined as FDR < 0.05. 
Biological pathway analysis 
 
To identify biological pathways differentially 
regulated by DNA methylation, we used the Gene-Set 
Enrichment Analysis (GSEA) which is a bioinformatics 
tool for determining  whether  an  a  priori  defined  set  
of genes shows statistically significant, concordant 
differences between two biological states (http:// 
software.broadinstitute.org/gsea/index.jsp) [37].  Based 
on a collection of the Molecular Signatures Database 
(MSigDB) of GSEA, we computed overlaps between our 
genes linked to significant CpGs identified in our analysis 
and gene sets in MSigDB. Statistical significance of the 
overlap with each gene set in MSigDB is obtained from 
the hypergeometric distribution of number of overlapping 
genes (k), number of genes in the query set (n), total 
number of genes in a MSigDB set (K) and number of all 
known genes (N). 
analysis  that  removed  all  CpGs  on  sex chromosomes, k −1   K N − K p = 1 −    

   
N 

 
we  only  dropped  Y-linked  CpGs  (147  sites)  but  kept ∑i  n − i   n  
all X-linked CpGs (11229 sites)  considering  that  all  
our samples are females. A total of 484637 CpG sites 
were  available  for  subsequent  analysis.  The  raw   and 
i=0      
normalized DNA methylation data are deposited in the 
Gene Expression Omnibus database (http://www.ncbi. 
nlm.nih.gov/geo/; accession no.  GSE80468). 
Correction   for   multiple   testing   was   done    by 
calculating the false discovery rate according to Benjamini 
and Hochberg [36]. 
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Software packages 
All statistical analyses were conducted under the   
R software environment for statistical computing and 
graphics (https://www.r-project.org/). DNA methylation 
data were analysed using the R package minfi (http:// 
bioconductor.org/packages/release/bioc/html/minfi.html) 
[35] for raw data preprocessing (quality control and 
normalization) and for statistical analysis. 
 
ACKNOWLEDGMENT AND FUNDING 
 
This work was supported by the Region of 
Southern Denmark 2012 research grant project no. 
12/6629 and partially supported by the Novo Nordisk 
Foundation Medical and Natural Sciences Research Grant 
NNF13OC0007493. 
 
CONFLICTS OF INTEREST 
 
The authors report no conflicts of interest. 
 
REFERENCES 
 
1. Solomon CG. The epidemiology of polycystic ovary 
syndrome. Prevalence and associated disease risks. 
Endocrinol Metab Clin North Am. 1999; 28:247–263. 
2. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. 
Polycystic ovary syndrome: etiology, pathogenesis and 
diagnosis. Nat Rev Endocrinol. 2011; 7:219–231. 
3. Diamanti-Kandarakis E, Piperi C, Spina J,Argyrakopoulou G, 
Papanastasiou L, Bergiele A, Panidis D. Polycystic ovary 
syndrome: the influence of environmental and genetic 
factors. Hormones (Athens). 2006; 5:17–34. 
4. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. 
Heritability of polycystic ovary syndrome in a Dutch twin- 
family study. J Clin Endocrinol Metab. 2006; 91:2100–2104. 
5. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, Li Z, You L, 
Zhao J, Liu J, Liang X, Zhao X, Zhao J, et al. Genome-wide 
association study identifies susceptibility loci for polycystic 
ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. 
Nat Genet. 2011; 43:55–59. 
6. Brower MA, Jones MR, Rotter JI, Krauss RM, Legro RS, 
Azziz R, Goodarzi MO. Further investigation in europeans 
of susceptibility variants for polycystic ovary syndrome 
discovered in genome-wide association studies of Chinese 
individuals. J Clin Endocrinol Metab. 2015; 100:E182–186. 
7. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. 
Androgen excess fetal programming of female reproduction: 
a developmental aetiology for polycystic ovary syndrome? 
Hum Reprod Update. 2005; 11:357–374. 
8. Xita N, Tsatsoulis A. Review: fetal programming of 
polycystic ovary syndrome by androgen excess: evidence 
from experimental, clinical, and genetic association studies. 
J Clin Endocrinol Metab. 2006; 91:1660–1666. 
9. Wu XY, Li ZL, Wu CY, Liu YM, Lin H, Wang SH, Xiao WF. 
Endocrine traits of polycystic ovary syndrome in prenatally 
androgenized female Sprague-Dawley rats. Endocr J. 2010; 
57:201–209. 
10. Xu N, Azziz R, Goodarzi MO. Epigenetics in polycystic 
ovary syndrome: a pilot study of global DNA methylation. 
Fertil Steril. 2010; 94:781–783. 
11. Shen HR, Qiu LH, Zhang ZQ, Qin YY, Cao C, Di W. 
Genome-wide methylated DNA immunoprecipitation 
analysis of patients with polycystic ovary syndrome. PLoS 
One. 2013; 8:e64801. 
12. Wang XX, Sun BF, Jiao J, Chong ZC, Chen YS, Wang XL, 
Zhao Y, Zhou YM, Li D. Genome-wide DNA methylation and 
gene expression patterns provide insight into polycystic ovary 
syndrome development. Oncotarget. 2014; 5:6603–6610. doi: 
10.18632/oncotarget.2224. 
13. Yu YY, Sun CX, Liu YK, Li Y, Wang L, Zhang W. Genome- 
wide screen of ovary-specific DNA methylation in polycystic 
ovary syndrome. Fertil Steril. 2015; 104:145–153. 
14. Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, Zhang B, Liang X, 
Li T, Chen J, Shen J, Zhao J, You L, et al. Genome-wide 
association study identifies eight new risk loci for polycystic 
ovary syndrome. Nat Genet. 2012; 44:1020–1025. 
15. Hayes MG, Urbanek M, Ehrmann DA,  Armstrong  LL, 
Lee JY, Sisk R, Karaderi T, Barber TM, McCarthy MI, 
Franks S, Lindgren CM, Welt CK, Diamanti-Kandarakis E, 
et al. Reproductive Medicine Network, Stener-Victorin E, 
Legro RS, Dunaif A. Genome-wide association of 
polycystic ovary syndrome implicates alterations in 
gonadotropin secretion in European ancestry populations. 
Nat Commun. 2015; 6:7502. 
16. Lee H, Oh JY, Sung YA, Chung H, Kim HL, Kim GS, Cho YS, 
Kim JT. Genome-wide association study identified new 
susceptibility loci for polycystic ovary syndrome. Hum 
Reprod. 2015; 30:723–731. 
17. Shim U, Kim HN, Lee H, Oh JY, Sung YA, Kim HL. 
Pathway Analysis Based on a Genome-Wide Association 
Study of Polycystic Ovary Syndrome. PLoS One. 2015; 
10:e0136609. 
18. Ma B, Wilker EH, Willis-Owen SA, Byun HM, Wong KC, 
Motta V, Baccarelli AA, Schwartz J, Cookson WO, 
Khabbaz K, Mittleman MA, Moffatt MF, Liang L. 
Predicting DNA methylation level across human tissues. 
Nucleic Acids Res. 2014; 42:3515–3528. 
19. Glintborg D, Hass Rubin K, Nybo M, Abrahamsen B, 
Andersen M.  Morbidity  and  medicine  prescriptions  in  
a nationwide Danish population of patients  diagnosed  
with polycystic ovary syndrome. Eur J Endocrinol. 2015; 
172:627–638. 
20. Petríková J, Lazúrová I, Yehuda S. Polycystic ovary 
syndrome and autoimmunity. Eur J Intern Med. 2010; 
21:369–371. 
21. Kachuei M, Jafari F, Kachuei A, Keshteli AH. Prevalence 
of autoimmune thyroiditis in patients with polycystic ovary 
syndrome. Arch Gynecol Obstet. 2012; 285:853–856. 
www.impactjournals.com/oncotarget 11 Oncotarget  
22. Garelli S, Masiero S, Plebani M, Chen S, Furmaniak J, 
Armanini D, Betterle C. High prevalence of chronic 
thyroiditis in patients with polycystic ovary syndrome. Eur 
J Obstet Gynecol Reprod Biol. 2013; 169:248–251. 
23. Du D, Li X. The relationship between thyroiditis and 
polycystic ovary syndrome: a meta-analysis. Int J Clin Exp 
Med. 2013; 25; 6:880–889. 
24. Novais Jde S, Benetti-Pinto CL, Garmes HM, Jales RM, 
Juliato CR. Polycystic ovary syndrome and chronic 
autoimmune thyroiditis. Gynecol Endocrinol. 2015; 31:48–51. 
25. Conway GS, Honour JW, Jacobs  HS.  Heterogeneity  of 
the polycystic ovary syndrome: clinical, endocrine and 
ultrasound features in 556 patients. Clin Endocrinol (Oxf). 
1989; 30:459–470. 
26. Zhang HY, Guo CX, Zhu FF, Qu PP, Lin WJ, Xiong J. 
Clinical characteristics, metabolic features, and phenotype 
of Chinese women with polycystic ovary syndrome: a 
large-scale case-control study. Arch Gynecol Obstet. 2013; 
287:525–531. 
27. Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, 
Luque-Ramírez M, Lasunción MA, Correig X. Metabolic 
heterogeneity in polycystic ovary syndrome is determined 
by obesity: plasma metabolomic approach using GC-MS. 
Clin Chem. 2012; 58:999–1009. 
28. Anzenbacher P, Anzenbacherová E. Cytochromes P450 
and metabolism of xenobiotics. Cell Mol Life Sci. 2001; 
58:737–747. 
29. Diaz L, Diaz-Munoz M, Gonzalez L, Lira-Albarran S, 
Larrea F, Mendez I. Prolactin in the immune system. 
Licensee inTech. 2013. http://dx.doi.org/10.5772/53538. 
30. Szosland K, Pawlowicz P, Lewiński A. Prolactin secretion 
in polycystic ovary syndrome (PCOS). Neuro Endocrinol 
Lett. 2015; 36:53–58. 
31. Filho RB, Domingues L, Naves L, Ferraz E, Alves A, 
Casulari LA. Polycystic ovary syndrome and 
hyperprolactinemia are distinct entities. Gynecol Endocrinol. 
2007; 23:267–272. 
32. Glintborg D, Altinok M, Mumm H, Buch K, Ravn P, 
Andersen M. Prolactin is associated with metabolic risk and 
cortisol in 1007 women with polycystic ovary syndrome. 
Hum Reprod. 2014; 29:1773–1779. 
33. Munro SK, Farquhar CM, Mitchell MD, Ponnampalam AP. 
Epigenetic regulation of endometrium during the menstrual 
cycle. Mol Hum Reprod. 2010; 16:297–310. 
34. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus 
workshop group. Revised 2003 consensus on diagnostic 
criteria and long-term health risks related to polycystic 
ovary syndrome (PCOS). Hum Reprod. 2004; 19: 41–47. 
35. Aryee M, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, 
Feinberg AP, Hansen KD, Irizarry RA. Minfi: a fexible  
and comprehensive Bioconductor package for analysis of 
Infinium DNA methylation microarrays. Bioinformatics. 
2014; 30:1363–1369. 
36. Benjamini,Y. The control of the false discovery rate in 
multiple testing under dependency. Ann. Stat. 2001; 
4:1165–1188. 
37. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, 
Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, 
Lander ES, Mesirov JP. Gene set enrichment analysis: a 
knowledge-based approach for interpreting genome-wide 
expression profiles. Proc Natl Acad Sci U S A. 2005; 
102:15545–15550. 
